These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19154404)

  • 1. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.
    Sato S; Itamochi H; Kigawa J; Oishi T; Shimada M; Sato S; Naniwa J; Uegaki K; Nonaka M; Terakawa N
    Cancer Sci; 2009 Mar; 100(3):546-51. PubMed ID: 19154404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting SRC in mucinous ovarian carcinoma.
    Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
    Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SRC and tubulin in mucinous ovarian carcinoma.
    Liu T; Hu W; Dalton HJ; Choi HJ; Huang J; Kang Y; Pradeep S; Miyake T; Song JH; Wen Y; Lu C; Pecot CV; Bottsford-Miller J; Zand B; Jennings NB; Ivan C; Gallick GE; Baggerly KA; Hangauer DG; Coleman RL; Frumovitz M; Sood AK
    Clin Cancer Res; 2013 Dec; 19(23):6532-43. PubMed ID: 24100628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
    Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
    Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4).
    Chen CF; Huang CJ; Kang WY; Hsieh JS
    World J Surg Oncol; 2008 Nov; 6():118. PubMed ID: 19014441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
    Torii Y; Kato R; Minami Y; Hasegawa K; Fujii T; Udagawa Y
    Anticancer Res; 2014 Jan; 34(1):107-15. PubMed ID: 24403450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
    Catalano V; Loupakis F; Graziano F; Torresi U; Bisonni R; Mari D; Fornaro L; Baldelli AM; Giordani P; Rossi D; Alessandroni P; Giustini L; Silva RR; Falcone A; D'Emidio S; Fedeli SL
    Br J Cancer; 2009 Mar; 100(6):881-7. PubMed ID: 19259089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
    Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
    Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.
    Sato N; Saga Y; Mizukami H; Wang D; Fujiwara H; Takei Y; Machida S; Ozawa K; Suzuki M
    Oncol Rep; 2012 May; 27(5):1336-40. PubMed ID: 22246397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
    Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.